Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 639027101 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Prescott Group Capital Management, L.L.C.
13G/A
Amendment 5
|
10.9% |
8/10/2026
Event 8/6/2026
|
|
| Prescott Group Capital Management, L.L.C. | 10.9% | ||
| Prescott Group Aggressive Small Cap LP | 10.9% | ||
| Prescott Group Aggressive Small Cap II LP | 10.9% | ||
| Prescott Group Aggressive Small Cap Master Fund GP | 10.9% | ||
| Frohlich Phil | 10.9% | ||
| BlackRock, Inc. 13G | 5.0% |
10/17/2025
Event 9/30/2025
|
|
| Dimensional Fund Advisors LP 13G | 5.2% |
10/9/2025
Event 9/30/2025
|
|
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
13D/A
Amendment 3
|
0.4% |
6/27/2025
Event 6/25/2025
|
|
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 0.4% | ||
| Fosun Pharma USA Inc. | 0% | ||
|
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
13D/A
Amendment 2
|
15.9% |
6/9/2025
Event 6/5/2025
|
|
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 15.9% | ||
| Fosun Pharma USA Inc. | 15.6% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 3 | 2.11 k | $26.8 k |
| 2026 Q2 | 156 | 15.9 M | $346 M |
| 2026 Q1 | 154 | 15.3 M | $367 M |
| 2025 Q4 | 148 | 14.7 M | $316 M |
| 2025 Q3 | 126 | 14.7 M | $228 M |
| 2025 Q2 | 121 | 14.3 M | $212 M |
| 2025 Q1 | 98 | 15.2 M | $191 M |
| 2024 Q4 | 94 | 15.3 M | $224 M |
| 2024 Q3 | 95 | 15.4 M | $209 M |
| 2024 Q2 | 105 | 15.2 M | $229 M |
| 2024 Q1 | 111 | 15.4 M | $320 M |
| 2023 Q4 | 111 | 15.3 M | $265 M |
| 2023 Q3 | 95 | 14.5 M | $238 M |
| 2023 Q2 | 82 | 14.5 M | $198 M |
| 2023 Q1 | 84 | 14.6 M | $139 M |
| 2022 Q4 | 89 | 14.6 M | $122 M |
| 2022 Q3 | 84 | 14.5 M | $119 M |
| 2022 Q2 | 87 | 14.5 M | $155 M |
| 2022 Q1 | 99 | 14.3 M | $241 M |
| 2021 Q4 | 98 | 14.4 M | $267 M |
| 2021 Q3 | 83 | 14.4 M | $211 M |
| 2021 Q2 | 80 | 13.5 M | $235 M |
| 2021 Q1 | 80 | 13.5 M | $317 M |
| 2020 Q4 | 69 | 13.6 M | $203 M |
| 2020 Q3 | 71 | 15.4 M | $178 M |
| 2020 Q2 | 68 | 15.2 M | $137 M |
| 2020 Q1 | 62 | 15.1 M | $123 M |
| 2019 Q4 | 61 | 15.1 M | $135 M |
| 2019 Q3 | 63 | 14.9 M | $123 M |
| 2019 Q2 | 58 | 14.6 M | $136 M |
| 2019 Q1 | 52 | 14.5 M | $135 M |
| 2018 Q4 | 58 | 14.6 M | $119 M |
| 2018 Q3 | 59 | 14.6 M | $128 M |
| 2018 Q2 | 56 | 14.6 M | $136 M |
| 2018 Q1 | 54 | 14.5 M | $160 M |
| 2017 Q4 | 56 | 14.4 M | $167 M |
| 2017 Q3 | 56 | 14.2 M | $144 M |
| 2017 Q2 | 61 | 14.1 M | $187 M |
| 2017 Q1 | 60 | 14.0 M | $140 M |
| 2016 Q4 | 62 | 14.0 M | $211 M |
| 2016 Q3 | 61 | 13.8 M | $222 M |
| 2016 Q2 | 59 | 13.8 M | $131 M |
| 2016 Q1 | 56 | 13.8 M | $133 M |
| 2015 Q4 | 55 | 13.9 M | $141 M |
| 2015 Q3 | 59 | 13.9 M | $168 M |
| 2015 Q2 | 62 | 13.9 M | $191 M |
| 2015 Q1 | 64 | 14.0 M | $184 M |
| 2014 Q4 | 67 | 14.1 M | $208 M |
| 2014 Q3 | 67 | 11.3 M | $168 M |
| 2014 Q2 | 69 | 11.6 M | $197 M |
| 2014 Q1 | 65 | 11.5 M | $159 M |